Clarke M, Gabrielsen O, Frampton J
Adv Exp Med Biol. 2024; 1459:341-358.
PMID: 39017851
DOI: 10.1007/978-3-031-62731-6_15.
Brayer K, Kang H, El-Naggar A, Andreasen S, Homoe P, Kiss K
Cancers (Basel). 2023; 15(5).
PMID: 36900183
PMC: 10000625.
DOI: 10.3390/cancers15051390.
Ciciro Y, Sala A
Oncogenesis. 2021; 10(2):19.
PMID: 33637673
PMC: 7910556.
DOI: 10.1038/s41389-021-00309-y.
Frerich C, Sedam H, Kang H, Mitani Y, El-Naggar A, Ness S
Cancers (Basel). 2019; 12(1).
PMID: 31877778
PMC: 7016764.
DOI: 10.3390/cancers12010045.
Wang X, Angelis N, Thein S
Gene. 2018; 665:6-17.
PMID: 29704633
PMC: 10764194.
DOI: 10.1016/j.gene.2018.04.065.
Reassessing the Potential of Myb-targeted Anti-cancer Therapy.
Liu X, Xu Y, Han L, Yi Y
J Cancer. 2018; 9(7):1259-1266.
PMID: 29675107
PMC: 5907674.
DOI: 10.7150/jca.23992.
Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis.
George O, Ness S
Cancers (Basel). 2014; 6(4):2049-71.
PMID: 25279451
PMC: 4276956.
DOI: 10.3390/cancers6042049.
A single amino acid change within the R2 domain of the VvMYB5b transcription factor modulates affinity for protein partners and target promoters selectivity.
Hichri I, Deluc L, Barrieu F, Bogs J, Mahjoub A, Regad F
BMC Plant Biol. 2011; 11:117.
PMID: 21861899
PMC: 3240579.
DOI: 10.1186/1471-2229-11-117.
Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL.
Zhou Y, ORourke J, Edwards J, Ness S
PLoS One. 2011; 6(8):e22880.
PMID: 21853052
PMC: 3154906.
DOI: 10.1371/journal.pone.0022880.
Dramatic repositioning of c-Myb to different promoters during the cell cycle observed by combining cell sorting with chromatin immunoprecipitation.
Quintana A, Zhou Y, Pena J, ORourke J, Ness S
PLoS One. 2011; 6(2):e17362.
PMID: 21364958
PMC: 3043100.
DOI: 10.1371/journal.pone.0017362.
Myb proteins: angels and demons in normal and transformed cells.
Zhou Y, Ness S
Front Biosci (Landmark Ed). 2011; 16(3):1109-31.
PMID: 21196221
PMC: 3570128.
DOI: 10.2741/3738.
c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz A
J Clin Invest. 2010; 120(2):593-606.
PMID: 20093773
PMC: 2810070.
DOI: 10.1172/JCI38030.
Myb-induced chromatin remodeling at a dual enhancer/promoter element involves non-coding rna transcription and is disrupted by oncogenic mutations of v-myb.
Wilczek C, Chayka O, Plachetka A, Klempnauer K
J Biol Chem. 2009; 284(51):35314-24.
PMID: 19841477
PMC: 2790961.
DOI: 10.1074/jbc.M109.066175.
Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.
ORourke J, Ness S
Mol Cell Biol. 2008; 28(6):2091-101.
PMID: 18195038
PMC: 2268396.
DOI: 10.1128/MCB.01870-07.
Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene.
Ivanova O, Braas D, Klempnauer K
Nucleic Acids Res. 2007; 35(21):7237-47.
PMID: 17959653
PMC: 2175353.
DOI: 10.1093/nar/gkm675.
The promoter regions of the Myb-regulated Adora2B and Mcm4 genes co-localize with origins of DNA replication.
Gundelach H, Braas D, Klempnauer K
BMC Mol Biol. 2007; 8:75.
PMID: 17822556
PMC: 2018721.
DOI: 10.1186/1471-2199-8-75.
Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain.
Mo X, Kowenz-Leutz E, Laumonnier Y, Xu H, Leutz A
Genes Dev. 2005; 19(20):2447-57.
PMID: 16195416
PMC: 1257399.
DOI: 10.1101/gad.355405.
Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1.
Lei W, Liu F, Ness S
Blood. 2005; 105(10):3855-61.
PMID: 15687240
PMC: 1895079.
DOI: 10.1182/blood-2004-08-3342.
v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter.
Chayka O, Kintscher J, Braas D, Klempnauer K
Mol Cell Biol. 2004; 25(1):499-511.
PMID: 15601869
PMC: 538795.
DOI: 10.1128/MCB.25.1.499-511.2005.
The glioma-amplified sequence 41 gene (GAS41) is a direct Myb target gene.
Braas D, Gundelach H, Klempnauer K
Nucleic Acids Res. 2004; 32(16):4750-7.
PMID: 15356292
PMC: 519106.
DOI: 10.1093/nar/gkh808.